Ernexa Therapeutics Inc. Warrants
ERNAW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.29K
Close$
$5.53
21484.4% upside
Current Fair Value
21484.4% upsideUndervalued by 21484.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $30,285.00 |
|---|---|
| Enterprise Value | $-4,648,715.00 |
| Earnings per Share | $-56 |
| Beta | 2.65 |
| Outstanding Shares | 1,183,000 |
Return
| Return on Equity | -383.28% |
|---|---|
| Return on Assets | -194.22% |
| Return on Invested Capital | -323.59% |
Valuation & Multiples
| P/E Ratio | -0.1 |
|---|---|
| PEG | -0.38 |
| Price to Sales | - |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.13 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.24 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-3.30
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Eterna Therapeutics Inc
2,018 employees
CEO: Sanjeev Luther
Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions. Its primary therapeutic, ERNA-101, is ...